Autolus Therapeutics (NASDAQ:AUTL) Hits New 52-Week Low – What’s Next?

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price hit a new 52-week low on Thursday . The company traded as low as $3.05 and last traded at $3.09, with a volume of 998117 shares. The stock had previously closed at $3.29.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AUTL. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Friday. Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 price objective on shares of Autolus Therapeutics in a research note on Monday, November 11th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.45.

Autolus Therapeutics Trading Up 2.3 %

The firm has a 50-day moving average of $3.91 and a two-hundred day moving average of $3.98. The firm has a market capitalization of $819.56 million, a PE ratio of -2.55 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the prior year, the firm posted ($0.26) earnings per share. Equities research analysts expect that Autolus Therapeutics plc will post -0.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Several institutional investors have recently bought and sold shares of AUTL. Wellington Management Group LLP raised its stake in shares of Autolus Therapeutics by 35.4% in the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after acquiring an additional 6,330,392 shares during the period. FMR LLC lifted its stake in shares of Autolus Therapeutics by 44.6% during the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after purchasing an additional 5,478,706 shares in the last quarter. Avoro Capital Advisors LLC acquired a new position in shares of Autolus Therapeutics during the first quarter worth about $78,765,000. Armistice Capital LLC boosted its position in shares of Autolus Therapeutics by 33.8% in the second quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock worth $21,750,000 after buying an additional 1,578,000 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Autolus Therapeutics by 82.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock valued at $35,020,000 after buying an additional 2,487,778 shares in the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.